Past observational studies have supported the use of hormone therapy (HT) to reduce vasomotor symptoms, uro genital atrophy, osteoporosis, colon cancer, dementia and coronary heart disease ( 1 -12 ) . As a result of these observational studies, previous general clinical consensus, supported by multiple specialty society recommendations, held that expected benefi ts of HT outweighed the known associated risks ( 13 -14 ) . However, more recent randomized trials assessing HT safety and effi cacy have dramatically changed recommendations regarding the use of HT. Studies such as the Heart and Estrogen/Progestin Replacement Study (HERS), the follow-up HERS II, and the Women's Health Initiative (WHI) have highlighted the lack of benefi t for longterm prevention of disease when evaluated in light of the unacceptable risk profi le ( 15 -17 ) .
In May 2002, the WHI Data and Safety Monitoring Board stopped the estrogen and progestin therapy (EPT) trial 2 years early on the basis of evidence of excess risk of invasive breast cancer, coronary heart disease, stroke, venous thromboembolism, and pulmonary embolism in women receiving treatment versus placebo ( 17 ) . These results were released to the public in July 2002, and the effect on HT use was swift and substantive. Buist et al. reported that the annualized rate of EPT discontinuation jumped from 2.5% to 13.8% -a 4.5-fold increase -by October 2002 ( 18 ) . In addition to stopping current therapy, women were half as likely to start EPT during that time period ( 18 We found that all communications, guidelines, and educational materials distributed by the HMOs after the release of the WHI EPT results encompassed part or all of the American College of Obstetricians and Gynecologists recommendations, including that EPT therapy should not be used for prevention of diseases such as cardiovascular disease, because of the small but signifi cant increased risk of conditions such as breast cancer, heart attack, and thrombosis; hormone therapies are appropriate for the relief of vasomotor symptoms, so long as a woman has weighed the risks and benefi ts with her doctor; and women who use EPT or ET should take the smallest effective dose for the shortest possible time and annually review the decision to take hormones ( 19 ) . Table 1 outlines the types of information distributed by the fi ve health plans and highlights the major points of the various recommendations. Every health plan released some form of communication, educational material, or guideline within 3 months of the release of WHI EPT trial results. Although reviewed materials were mainly directed toward physicians, pharmacists, and other clinical personnel, additional information was also made available to patients through a variety of sources such as Web sites, which sometimes included links to other relevant sites, phone hotlines, pamphlets, and guidebooks ( Table 2 ) . Consistent with the new recommendations, the follow-up EPT discontinuation rate across the HMOs was higher among women identifi ed with cardiovascular disease compared to women with no comorbidity ( 20 ) . In addition, the relative risk for EPT discontinuation was signifi cantly higher among women with known diabetes, but not among women with known fractures compared to women with no comorbidity ( 20 ) .
All organizations used a team approach for information collection and document preparation. Members of these teams varied by HMO but were pulled from the following divisions/ departments: Clinical Improvement and Education, Drug Information, Drug Utilization, Endocrinology, Family Practice, Health Education, Internal Medicine, Obstetrics/ Gynecology, Medical Informatics, Medical Education, Patient Representation, Preventive Medicine, and Women's Health Care. All documents were published as informational only and were not intended to substitute for independent clinical judgment by providers but, rather, to be used as a resource.
Connelly et al. has shown that provider opinion is the leading infl uence in a woman's decision about HT followed closely by reports in the media ( 21 ) . Similarly, Ettinger et al. reported most women (93%) had heard about the WHI fi ndings. However, only 57% considered the quality of the information to be good, regardless of the source: media, health plan, or health care practitioner ( 22 ) . The widespread media attention of the WHI EPT trial results very likely affected the decision of many women to stop EPT. However, what effect individual health plan responses had on a physician or patient's decision to discontinue or not initiate EPT remains unclear. This report illustrates despite the variation in the types of material distributed to physicians and other clinical personnel, the overall decrease in EPT use was remarkably similar across the different HMOs (data not shown). Given the timeliness and consistency in therapeutic recommendations across all sites, these data indicate that provider opinions, po tentially informed to some degree by health plan guideline and educational materials, may have played a role in decision making. They also indicate that timeliness of information is important, irrespective of information format.
In conclusion, almost immediately following the release of the WHI EPT trial results, there was a signifi cant decline in EPT use among women ( 18 , 20 , 22 -25 ) . Although many studies reported on the changes of HT use among women, there is a paucity of information concerning the response of health plans to the release of these data. This report highlights that all HMOs surveyed reacted quickly by circulating updated materials relating to HT. These data indicate that administrators at the various HMOs were responsive in providing the most current evidence-based information as quickly as possible, although it remains unclear whether these HT recommendations infl uence physician or patient decision making. Further studies will be necessary to assess the longterm effect of institutional educational material and guidelines on prescribing patterns. 
